BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

633 related articles for article (PubMed ID: 22212313)

  • 41. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study.
    Humaidan P; Bredkjaer HE; Bungum L; Bungum M; Grøndahl ML; Westergaard L; Andersen CY
    Hum Reprod; 2005 May; 20(5):1213-20. PubMed ID: 15760966
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of GnRH antagonist protocol with or without oral contraceptive pill pretreatment and GnRH agonist low-dose long protocol in low responders undergoing IVF/intracytoplasmic sperm injection.
    Kim CH; Jeon GH; Cheon YP; Jeon I; Kim SH; Chae HD; Kang BM
    Fertil Steril; 2009 Nov; 92(5):1758-60. PubMed ID: 19523618
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Gonadotropin-releasing hormone agonist combined with a reduced dose of human chorionic gonadotropin for final oocyte maturation in fresh autologous cycles of in vitro fertilization.
    Shapiro BS; Daneshmand ST; Garner FC; Aguirre M; Thomas S
    Fertil Steril; 2008 Jul; 90(1):231-3. PubMed ID: 17981269
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Minimal stimulation using recombinant follicle-stimulating hormone and a gonadotropin-releasing hormone antagonist in women of advanced age.
    Weghofer A; Margreiter M; Bassim S; Sevelda U; Beilhack E; Feichtinger W
    Fertil Steril; 2004 Apr; 81(4):1002-6. PubMed ID: 15066455
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of luteal estradiol patch and gonadotropin-releasing hormone antagonist suppression protocol before gonadotropin stimulation versus microdose gonadotropin-releasing hormone agonist protocol for patients with a history of poor in vitro fertilization outcomes.
    Weitzman VN; Engmann L; DiLuigi A; Maier D; Nulsen J; Benadiva C
    Fertil Steril; 2009 Jul; 92(1):226-30. PubMed ID: 18675961
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Does prolonged pituitary down-regulation with gonadotropin-releasing hormone agonist improve the live-birth rate in in vitro fertilization treatment?
    Ren J; Sha A; Han D; Li P; Geng J; Ma C
    Fertil Steril; 2014 Jul; 102(1):75-81. PubMed ID: 24746740
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A preliminary study on reduced dose (33 or 25 microg) gonadotropin-releasing hormone agonist long protocol for multifollicular ovarian stimulation in patients with high basal serum follicle-stimulating hormone levels undergoing in vitro fertilization-embryo transfer.
    Ku SY; Choi YS; Jee BC; Suh CS; Choi YM; Kim JG; Moon SY; Kim SH
    Gynecol Endocrinol; 2005 Oct; 21(4):227-31. PubMed ID: 16316845
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Luteal-phase ovarian stimulation is a feasible method for poor ovarian responders undergoing in vitro fertilization/intracytoplasmic sperm injection-embryo transfer treatment compared to a GnRH antagonist protocol: A retrospective study.
    Wei LH; Ma WH; Tang N; Wei JH
    Taiwan J Obstet Gynecol; 2016 Feb; 55(1):50-4. PubMed ID: 26927248
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evaluation of GnRH antagonist pretreatment before ovarian stimulation in a GnRH antagonist protocol in normal ovulatory women undergoing IVF/ICSI: a randomized controlled trial.
    Zhang Y; Liu L; Qin J; Huang H; Xue L; Wang S; Tan W
    Reprod Biol Endocrinol; 2021 Oct; 19(1):158. PubMed ID: 34641897
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of GnRH agonists and antagonists in normoresponder IVF/ICSI in Turkish female patients.
    Moraloglu O; Kilic S; Karayalçin R; Yuksel B; Tasdemir N; Işik A; Ugur M
    Adv Ther; 2008 Mar; 25(3):266-73. PubMed ID: 18345521
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Minimal stimulation IVF with late follicular phase administration of the GnRH antagonist cetrorelix and concomitant substitution with recombinant FSH: a pilot study.
    Pelinck MJ; Vogel NE; Hoek A; Arts EG; Simons AH; Heineman MJ
    Hum Reprod; 2005 Mar; 20(3):642-8. PubMed ID: 15608031
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Clinical applications of different doses of leuprorelin acetate in in vitro fertilization-embryo transfer].
    Wang L; Zhang WX; Jiang H
    Zhonghua Fu Chan Ke Za Zhi; 2012 Dec; 47(12):910-4. PubMed ID: 23324190
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of GnRH agonists and antagonists in assisted reproduction cycles of patients at high risk of ovarian hyperstimulation syndrome.
    Ragni G; Vegetti W; Riccaboni A; Engl B; Brigante C; Crosignani PG
    Hum Reprod; 2005 Sep; 20(9):2421-5. PubMed ID: 15890731
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study.
    Vuong TN; Ho MT; Ha TD; Phung HT; Huynh GB; Humaidan P
    Fertil Steril; 2016 Feb; 105(2):356-63. PubMed ID: 26523330
    [TBL] [Abstract][Full Text] [Related]  

  • 55. GnRH antagonist administered twice the day before hCG trigger combined with a step-down protocol may prevent OHSS in IVF/ICSI antagonist cycles at risk for OHSS without affecting the reproductive outcomes: a prospective randomized control trial.
    Prapas Y; Ravanos K; Petousis S; Panagiotidis Y; Papatheodorou A; Margioula-Siarkou C; Iuliano A; Gullo G; Prapas N
    J Assist Reprod Genet; 2017 Nov; 34(11):1537-1545. PubMed ID: 28776117
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Intranasal gonadotropin-releasing hormone agonist (GnRHa) for luteal-phase support following GnRHa triggering, a novel approach to avoid ovarian hyperstimulation syndrome in high responders.
    Bar-Hava I; Mizrachi Y; Karfunkel-Doron D; Omer Y; Sheena L; Carmon N; Ben-David G
    Fertil Steril; 2016 Aug; 106(2):330-3. PubMed ID: 27114332
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Repeated doses of GnRH antagonist at midcycle in artificial frozen embryo transfer cycles may not affect pregnancy outcomes.
    Palmerola KL; Hsu JY; Grossman LC; Sauer MV; Lobo RA
    Gynecol Endocrinol; 2017 Apr; 33(4):301-305. PubMed ID: 28010150
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical efficacy of the gonadotropin-releasing hormone antagonist, ganirelix, in Korean women undergoing controlled ovarian hyperstimulation for in vitro fertilization and embryo transfer with recombinant follicle-stimulating hormone.
    Moon SY; Ku SY; Kim SM; Jee BC; Suh CS; Choi YM; Kim JG; Kim SH
    J Obstet Gynaecol Res; 2005 Jun; 31(3):227-35. PubMed ID: 15916659
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Multifollicular recruitment in combination with gonadotropin-releasing hormone antagonist increased pregnancy rates in intrauterine insemination cycles.
    Gómez-Palomares JL; Acevedo-Martín B; Chávez M; Manzanares M; Ricciarelli E; Hernández ER
    Fertil Steril; 2008 Mar; 89(3):620-4. PubMed ID: 17678911
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy of low-dose human chorionic gonadotropin (hCG) in a GnRH antagonist protocol.
    Koichi K; Yukiko N; Shima K; Sachiko S
    J Assist Reprod Genet; 2006 May; 23(5):223-8. PubMed ID: 16786420
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.